InMode Ltd. (NASDAQ:INMD) Shares Bought by Hotchkis & Wiley Capital Management LLC

Hotchkis & Wiley Capital Management LLC grew its holdings in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 12.9% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 720,750 shares of the healthcare company's stock after buying an additional 82,100 shares during the period. Hotchkis & Wiley Capital Management LLC owned 0.86% of InMode worth $12,217,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Holocene Advisors LP bought a new position in InMode in the third quarter worth $853,000. Wasatch Advisors LP raised its holdings in InMode by 14.6% in the third quarter. Wasatch Advisors LP now owns 421,635 shares of the healthcare company's stock worth $7,147,000 after purchasing an additional 53,673 shares in the last quarter. Edgestream Partners L.P. bought a new position in InMode in the third quarter worth $634,000. Verition Fund Management LLC increased its holdings in shares of InMode by 18.2% during the third quarter. Verition Fund Management LLC now owns 37,196 shares of the healthcare company's stock valued at $630,000 after acquiring an additional 5,739 shares in the last quarter. Finally, Martingale Asset Management L P increased its holdings in shares of InMode by 147.2% during the third quarter. Martingale Asset Management L P now owns 62,360 shares of the healthcare company's stock valued at $1,057,000 after acquiring an additional 37,135 shares in the last quarter. 68.04% of the stock is owned by hedge funds and other institutional investors.

InMode Trading Up 1.5 %

INMD traded up $0.28 on Wednesday, hitting $19.40. 1,149,152 shares of the company's stock traded hands, compared to its average volume of 1,324,030. The company's 50 day simple moving average is $17.77 and its 200-day simple moving average is $17.52. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of 10.49 and a beta of 2.07. InMode Ltd. has a one year low of $14.87 and a one year high of $26.80.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Barclays dropped their price objective on InMode from $29.00 to $27.00 and set an "overweight" rating on the stock in a research report on Monday, October 14th. Needham & Company LLC reaffirmed a "hold" rating on shares of InMode in a research report on Thursday, October 31st. Finally, BTIG Research assumed coverage on InMode in a research report on Thursday, October 17th. They set a "buy" rating and a $25.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $22.60.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.